FATE THERAPEUTICS INC Restructuring and Related Cost, Number of Positions Eliminated, Period Percent
FATE THERAPEUTICS INC (FATE) reported Restructuring and Related Cost, Number of Positions Eliminated, Period Percent of 60.00% for the 9-month period ending 2023-09-30, per its 10-Q filed 2023-11-08.
Discontinued › Expense Statement › Operating Expenses
us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent · last filed 2024-02-26
- FATE THERAPEUTICS INC restructuring and related cost, number of positions eliminated, period percent for the quarter ending 2023-03-31 was 60.00%.
| Period end | Restructuring and Related Cost, Number of Positions Eliminated, Period Percent 1 month | Restructuring and Related Cost, Number of Positions Eliminated, Period Percent 3 month | Restructuring and Related Cost, Number of Positions Eliminated, Period Percent 6 month | Restructuring and Related Cost, Number of Positions Eliminated, Period Percent 9 month |
|---|---|---|---|---|
| 2023-09-30 | 60.00% 10-Q · filed 2023-11-08 | |||
| 2023-06-30 | 60.00% 10-Q · filed 2023-08-08 | |||
| 2023-03-31 | 60.00% 10-Q · filed 2023-05-03 | |||
| 2023-01-31 | 60.00% 10-K · filed 2024-02-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Liminatus Pharma, Inc. (LIMN) | United States | $0.282B | |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| X4 Pharmaceuticals, Inc (XFOR) | United States | $0.297B | -4.99 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |
| SAB Biotherapeutics, Inc. (SABS) | United States | $0.306B | -25.49 |
| Century Therapeutics, Inc. (IPSC) | United States | $0.306B | -4.02 |
| Lineage Cell Therapeutics, Inc. (LCTX) | United States | $0.241B | -10.35 |